<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00675922</url>
  </required_header>
  <id_info>
    <org_study_id>95-096</org_study_id>
    <nct_id>NCT00675922</nct_id>
  </id_info>
  <brief_title>Study of the Treatment of Burn Wounds With Antimicrobial Topical Soaks</brief_title>
  <acronym>Soaks</acronym>
  <official_title>Comparing the Use of Sulfamylon 5%, Dakins 0.025%, Cerium, Silver Nitrate 5% and/or Other Topical Antimicrobial Products for the Treatment of Excised and/or Grafted Burn Wounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine effectiveness of various antimicrobial solutions on burn wounds (infections, wound
      healing, length of hospital stay).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients were treated with both Sulfamylon soaks and Silver nitrate soaks on different burn
      areas. These two areas were then compared for incidence (percentage) of infections.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Data inconclusive.
  </why_stopped>
  <start_date>July 1995</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infection Rate</measure>
    <time_frame>Acute hospitalization following burn injury: admission to discharge (1-20 weeks)</time_frame>
    <description>Percent of infections following antimicrobial topical treatment with Sulfamylon vs Silver Nitrate Soaks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay With Various Antimicrobial Solutions for Burn Patients</measure>
    <time_frame>Admission to burn unit to discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Burn</condition>
  <arm_group>
    <arm_group_label>Sulfamylon 5% and Silver Nitrate Soaks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Application of Sulfamylon 5% Solution and Silver Nitrate soaked dressings to two different burned area. Sites were then monitored for infections during hospitalization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfamylon 5% and Silver Nitrate Soaks</intervention_name>
    <description>Application of Sulfamylon and Silver Nitrate Solution to burn wound daily</description>
    <arm_group_label>Sulfamylon 5% and Silver Nitrate Soaks</arm_group_label>
    <other_name>Sulfamylon</other_name>
    <other_name>Silver Nitrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Burn Injury requiring excisional therapy

          -  Hospitalization required until wounds are closed

        Exclusion Criteria:

          -  Known hypersensitivity to products

          -  Outpatient treatment for burn injury
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David N Herndon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>May 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2008</study_first_posted>
  <results_first_submitted>August 6, 2012</results_first_submitted>
  <results_first_submitted_qc>December 10, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 18, 2013</results_first_posted>
  <last_update_submitted>December 10, 2012</last_update_submitted>
  <last_update_submitted_qc>December 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Burn</keyword>
  <keyword>Wounds</keyword>
  <keyword>Wound infection</keyword>
  <keyword>Topical antimicrobials</keyword>
  <keyword>Cerium</keyword>
  <keyword>Dakins</keyword>
  <keyword>Sulfamylon Soaks</keyword>
  <keyword>Silver Nitrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Silver Nitrate</mesh_term>
    <mesh_term>Mafenide</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients admitted to Burn ICU with acute burn injury were eligible for recruitment</recruitment_details>
      <pre_assignment_details>Patients consented were randomized to one or two of the treatment medications.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sulfamylon Solution 5% and Silver Nitrate Soaks</title>
          <description>Application of Sulfamylon 5% and Silver Nitrate Solution soaked dressings to a burned area</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sulfamylon vs Silver Nitrate Solution</title>
          <description>Application of Sulfamylon 5% and Silver Nitrate Solution soaked dressings to a burned area</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="98"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Infection Rate</title>
        <description>Percent of infections following antimicrobial topical treatment with Sulfamylon vs Silver Nitrate Soaks.</description>
        <time_frame>Acute hospitalization following burn injury: admission to discharge (1-20 weeks)</time_frame>
        <population>Percent of sites treated with sulfamylon of Silver Nitrate soaks that developed infections</population>
        <group_list>
          <group group_id="O1">
            <title>Percent Infections:Sulfamylon Site</title>
            <description>Percent of sites that developed infections with Sulfamylon soaks</description>
          </group>
          <group group_id="O2">
            <title>Percent Infections: Silver Nitrate Site</title>
            <description>Percent of sites that developed infections with Silver Nitrate soaks</description>
          </group>
        </group_list>
        <measure>
          <title>Infection Rate</title>
          <description>Percent of infections following antimicrobial topical treatment with Sulfamylon vs Silver Nitrate Soaks.</description>
          <population>Percent of sites treated with sulfamylon of Silver Nitrate soaks that developed infections</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" spread=".05"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospital Stay With Various Antimicrobial Solutions for Burn Patients</title>
        <time_frame>Admission to burn unit to discharge</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1995-2008</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sulfamylon Soaks, Silver Nitrate Soaks</title>
          <description>Patients receive both treatments and each treated site is compared.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <description>2001: 70% burn patient blood sugar decreased to 30 while on insulin drip. Glucose treated and insulin drip turned off. PI opinion is AE not related to study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <description>2001: 70% burn patient blood glucose decreased to 35 while on insulin drip. Glucose treated and insulin drip stopped. PI opinion, AE is not related to study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Invasive infection, MOF, death</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>2001: 74% burn admitted with invasive infection, developed multi organ failure and expired. PI opinion is AE is unlikely related to study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Sepsis, multi organ failure and death</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>2001: 85% burn admitted with invasive infections became septic, developed renal failure then multi organ failure. Patient removed from respiratory support and expired. PI opinion, AE is possibly related to study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal failure, death</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>2001: 90% burn admitted with renal failure. After patient was 95% grafted and healed, renal failure worsened and patient expired. PI opinion is AE unlikely related to study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Patient aspiration and death</sub_title>
                <description>2001: 62% burn after discharge, patient aspirated during the night ACLS provided, patient expired. PI opinion is AE not related to study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>pneumothorax</sub_title>
                <description>2001: 70% burn patient, pneumothorax occured during subclavian IV line placement for surgery. PI opinion is AE is not related to study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>chest tube fell out</sub_title>
                <description>2001: 70% burn, chest tube fell out while patient was being moved. PI opinion, AE not related to study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ischemia of leg</sub_title>
                <description>2001: 80% burn patient, during Arterial IV line placement for surgery, R leg became ischemic. Anticoagulants given. Patient discharged without complications. PI opinion is AE is not related to study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin, opened wound</sub_title>
                <description>42% burn, patient fell and opened a wound in groin area. PI opinion, AE not related to study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>open wound</sub_title>
                <description>2003: 42% burn patient scratched biopsy site that had been sutured shut, opening a wound. PI opinion, AE not related to study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Herndon, MD</name_or_title>
      <organization>University of Texas Medical Branch</organization>
      <phone>409-770-6731</phone>
      <email>dherndon@utmb.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

